Providing high-quality, ethically-sourced umbilical cord blood, umbilical cord, placental tissue, neonatal foreskin, adult peripheral blood and leukopaks, and a variety of isolated cells.
Following best practices and in adherence with American College of Obstetrics and Gynecology (ACOG) delayed cord clamping guidelines, OrganaBio offers placenta, umbilical cord, and umbilical cord blood tissues and cells. Adult leukapheresis and birth tissue products are collected in FDA-registered blood and tissue establishments with donor safety and well-being in the forefront.
All products are supported by quality and regulatory documentation to facilitate the rapid development of cell-based therapies.
OrganaBio’s portfolio of human tissue and tissue-derived cells is designed for the development of allogeneic cell therapies. Products are provided in various formats and customizable specifications, with delivery available on the same or next day after collection*.
OrganaBio offers “off-the-shelf”, ready to ship products for preclinical research, as well as custom and cGMP-compliant products for clinical development and manufacturing.
*location dependent
OrganaBio maintains an ethnically diverse donor pool. OrganaBio places an emphasis on having a highly recallable donor pool to ensure clients’ program success. Customers can view product inventory and select cell lots based on donor characteristics such as gender, age, race, ethnicity, blood type, HLA genotype, immunophenotype, CMV/EBV status, BMI, and smoking status.
OrganaBio maintains an ethnically diverse donor pool. OrganaBio places an emphasis on having a highly recallable donor pool to ensure clients’ program success. Customers can view product inventory and select cell lots based on donor characteristics such as gender, age, race, ethnicity, blood type, HLA genotype, immunophenotype, CMV/EBV status, BMI, and smoking status.
Designed for allogeneic cell therapy development, OrganaBio’s cell-based products are HLA typed, giving researchers the ability to review high resolution genotyping by NGS for HLA-A, B, C, DR, DQ, DP on all donors. Developers can select products from donors with common or rare HLA alleles to test the effects of HLA matching or mismatching on cell persistence, immune response, and immune rejection.
Designed for allogeneic cell therapy development, OrganaBio’s cell-based products are HLA typed, giving researchers the ability to review high resolution genotyping by NGS for HLA-A, B, C, DR, DQ, DP on all donors. Developers can select products from donors with common or rare HLA alleles to test the effects of HLA matching or mismatching on cell persistence, immune response, and immune rejection.
OrganaBio’s products are backed by defined attributes and regulatory oversight, yielding cell products with high purity and viability. Each product lot is accompanied by a comprehensive Certificate of Analysis with extensive CQA data. Access to the immunophenotyping profile enables selection of material based on specific cell subset distribution, such as T cells, B cells, monocytes, or NK cells composition, decreasing process development timelines for our customers.
OrganaBio’s products are backed by defined attributes and regulatory oversight, yielding cell products with high purity and viability. Each product lot is accompanied by a comprehensive Certificate of Analysis with extensive CQA data. Access to the immunophenotyping profile enables selection of material based on specific cell subset distribution, such as T cells, B cells, monocytes, or NK cells composition, decreasing process development timelines for our customers.
OrganaBio’s products are manufactured with clinical translation in mind. OrganaBio screens donors and determines donor eligibility in accordance with US FDA 21 CFR 630 and 1271 and the current AABB Donor History Questionnaire (DHQ). GTP- and GMP-compliant SOPs are designed for flexibility and scalability to meet each customer’s unique needs. Clinical grade products are manufactured in an ISO 7 cleanroom within OrganaBio’s cGMP manufacturing facility.
OrganaBio’s products are manufactured with clinical translation in mind. OrganaBio screens donors and determines donor eligibility in accordance with US FDA 21 CFR 630 and 1271 and the current AABB Donor History Questionnaire (DHQ). GTP- and GMP-compliant SOPs are designed for flexibility and scalability to meet each customer’s unique needs. Clinical grade products are manufactured in an ISO 7 cleanroom within OrganaBio’s cGMP manufacturing facility.
Proprietary Supply Chain
OrganaBio owns and operates the company’s supply chains for controlled, traceable, and ethical collection of perinatal and adult tissues.
Join our community to receive tailored insights and resources. You can unsubscribe at any time.
Project Manager
Andrew joins OrganaBio as a project manager with varied experience in project management, client relations, and process improvement.
Prior to OrganaBio, Andrew was a client relations manager for the cGMP nucleic acids business unit at Aldevron, coordinating and managing contracts at each stage of the contract lifecycle in support of cell and gene therapy program development. Andrew supported small- and large-scale biotechnology and pharmaceutical clients anywhere from pre-IND work through commercial supply chain establishment. Before Aldevron, Andrew was a project manager for the commercialization and business development department for Sanford Health, a worldwide hospital institution. At Sanford Health, Andrew helped manage medical device patent and prototype development efforts for employee innovations primarily in the cardiovascular, neurovascular, and software spaces. Andrew was also an engineer for Atirix Medical Systems and supported the buildout of automated analysis worksheets to streamline radiology department quality control procedures.
Andrew received his Bachelor of Science in Physics from Minnesota State University Moorhead and his Master of Science in Biomedical Engineering from the University of Minnesota. At the University of Minnesota, Andrew was part of the Center for Magnetic Resonance Research, assisting efforts to automate MRI dataset registration and workflow improvement.
Associate Director, QC and Analytical Development
Michael Dee has spent the last 17 years researching the immune system. Initially studying the recombinant cytokine IL-2 and its role in T cell subset differentiation and function at the University of Miami. He also helped elucidate the lower level of TCR diversity of T regs required to prevent autoimmunity in mice. Michael also supported construction, cloning, production, purification, and testing both in vitro and in vivo a novel IL-2/IL2Rα complex currently under clinical development with BMS. Michael also was a member of the department of immunology’s program project delineating the effect of a novel Eg7GP96 heat shock protein vaccine on tumor immunity.
While at Immunity Bio (formerly Altor Biosciences), he helped to characterize over 20 novel drugs for immune modulation and treatment of cancer. After Immunity Bio, Michael was a founding team member of HCW Biologics, where he continued his role in design and initial production and characterization of several novel biologics. He has experience with proof of principle experiments with the generation CAR-NK and CAR T cells. His research at HCW was highlighted by his discovery of a process using novel biologics to activate and expand CIML NK cells. The process and rights were sold to Wugen and is currently in Phase I clinical trials. He also is listed as an Inventor on patent number: US20210268022A1 on method of activating regulatory T cells.
Senior Cell Processing Specialist
Principal Scientist
Director, Regional Scientific Sales
Marisa has experience leading marketing and sales life sciences programs for over a decade. Originally a lab researcher, she made the jump to marketing & sales in life sciences and never looked back.
At OrganaBio, she connects cell therapy developers on the West coast and in Asia with the healthy donor starting materials they need to develop their therapies. Prior to OrganaBio, she was the cell therapy marketing lead at Invetech, heading the launch of the company’s first cell therapy product. Marisa has led marketing programs at clinical supply companies Sherpa Clinical Packaging and PCI Pharma Services. In her spare time, Marisa enjoys traveling, eating, and pretending she’s a tennis player. She has a Bachelor of Arts in Biology from Reed College and an MBA from Portland State University.
Senior Director, Tissue Procurement
Vice President, Operations
Vice President, Quality & Regulatory Affairs
Senior Director, Quality Assurance
Danielle Smyla, M.S., brings 14 years of Quality Assurance and GMP experience in the Biotechnology and Medical Device industries. Ms. Smyla is an established Quality Leader with expertise in the implementation, management and continuous improvement of Quality Management Systems for GMP operations.
Prior to joining OrganaBio, Danielle was a key member of the Quality Management team at Canon BioMedical, where she led the cross-functional development and implementation of their Quality Management System. She also managed a team of Quality Specialists and Sr. Specialists, coaching them in the implementation, management and identification of improvements to quality processes.
Ms. Smyla’s Quality-focused career is complimented by valuable hands-on experience in GMP product manufacturing, as well as R&D laboratory experimentation and formulation work in support of product development.
Danielle has earned a Master’s in Biotechnology from the Johns Hopkins University and a Bachelor of Science in Chemistry from the George Washington University.
Chief Executive Officer
Justin Irizarry brings more than 17 years of entrepreneurial experience and executive-level leadership of business operations, finance, corporate development, and M&A.
Previously, Justin co-founded OrthoNOW, the nation’s only network of immediate orthopedic care facilities. He led OrthoNOW through its various stages of growth and development, and his success has been featured in numerous publications, such as Entrepreneur Magazine, CFO Magazine, the South Florida Business Journal, the Miami Herald, the Orlando Sentinel, MedCity News, and Becker’s Hospital Review and the Pivotal Leader podcast.
Prior to the healthcare industry, Justin was a Wall Street investment banker at Scott-Macon, Ltd., where he helped build the Education and Information Group. As an investment banker, he was responsible for sourcing and executing transactions between $50 million and $350 million, running the group’s day-to-day activities, and developing its long-term growth and technology strategies.
Justin earned a Bachelor of Arts degree in economics from Cornell University – where he was a four-year varsity baseball scholar-athlete – and a Master of Business Administration from The Wharton School at the University of Pennsylvania – where he was a Joseph Wharton Fellow. He has also earned the Chartered Financial Analyst® (CFA) designation, the most respected and recognized investment designation in the world.
Justin is the recipient of numerous honors and awards, including South Florida Business Journal’s 40 Under 40, South Florida Business Journal’s CFO of the Year, South Florida Business & Wealth’s Up and Comer Award, Hispanic Unity of Florida Foundation’s American Dreamer Award, and Diversity MBA Magazine’s Top 100 Under 50 Executive Leaders.
He has been an invited speaker at Columbia University’s Business School, University of Miami’s Business School, The Society for Healthcare Strategy & Market Development, South Florida Business Journal’s Roundtable Series, the South Florida Executive Roundtable, the American Academy of Orthopedic Executives, and the Coral Gables Chamber of Commerce.
Chief Business Officer
Dr. Baraniak is a proven strategic thinker, problem solver and leader who brings 20 years of expertise in stem cells and tissue engineering, coupled with a keen business acumen, to OrganaBio. Dr. Baraniak has published multiple peer-reviewed papers and book chapters on the use of stem cells and biomaterials in cardiac repair and regeneration and is routinely invited to speak at conferences.
Before joining OrganaBio, Priya was a founding member of RoosterBio and was a vital member of the company’s Leadership Team. At RoosterBio, Priya leveraged her technical expertise to build and rapidly scale the company’s sales and marketing engines in a fast-paced start-up environment, delivering impressive growth in revenue year-over-year. Additionally, in her role as Business Development lead at RoosterBio, Priya structured, negotiated and executed multiple strategic partnerships for aggressive growth of the organization.
Priya’s industry experience includes a role as Senior Director of R&D for Garnet BioTherapeutics, a clinical-stage stem cell-based regenerative medicine company, where Priya led multiple projects on tissue repair and regeneration using mesenchymal stem cell (MSC)-based therapeutics and devices. While at Garnet Bio, Priya also worked on the company’s FDA filings, contributed to drafting and prosecuting the company’s patent portfolio, managed CRO, CMO and industry partner relationships and actively participated in establishing Garnet’s strategic R&D plan, thereby gaining critical insights into business operations across a small organization.
Priya’s scientific training began as an undergraduate student at Duke University, where she earned a Bachelor of Science in Engineering (BSE) from Duke University in 2001 after double majoring in Electrical Engineering and Biomedical Engineering. While at Duke, Priya conducted research in the lab of Dr. Doris A. Taylor on the use of skeletal myoblasts and stem cells for cardiac repair and regeneration. Priya went on to receive her Ph.D. in Bioengineering from the University of Pittsburgh in 2008. She completed her dissertation research in the laboratory of Dr. William R. Wagner working on developing a controlled release biodegradable elastomer for applications in cardiovascular regenerative medicine. In 2008, Priya joined Dr. Todd McDevitt’s lab in the Department of Biomedical Engineering at Georgia Tech and Emory University as a post-doctoral fellow. Her post-doctoral research as an American Heart Association Fellow focused on harnessing the secretome and isolating the extracellular matrix from MSCs and other cell types, including pluripotent stem cells, for cardiac tissue repair and regeneration. Priya co-authored many grants while a post-doc and went on to contribute critical sections to a NIST grant that resulted in the first ever National Cell Manufacturing Consortium in the United States.
Senior Director, Scientific Affairs
Sarah Alter, Ph.D., has 15 years of immunology research experience which includes autoimmunity, cancer, and infectious disease.
Before her position at OrganaBio, Sarah was responsible for leading a team of scientists at Altor Bioscience where she facilitated the advancement of Altor’s technologies. As a Research and Development Manager, Dr. Alter coordinated immunotherapy-focused preclinical and clinical studies and contributed to the progress of Altor’s drug discovery and therapeutic applications.
Sarah received her Doctor of Philosophy from the University of Miami, Miller School of Medicine. She is also a registered Patent Agent, licensed to practice before the United States Patent and Trademark Office. Her work was published in many peer-reviewed journals and presented at national and international business and scientific meetings.
Director, Birth Tissue Product Sales
Carlos Carballosa is a biomedical engineer with over 8 years of stem cell research experience with broad expertise in the culture, differentiation, and cryopreservation of adult stem cell populations. Carlos earned his bachelors, masters and doctorate degrees in Biomedical Engineering from the University of Miami, where his research focused on the effects of nicotine and electronic cigarette vapor exposure on the regeneration potential of adult stem cells. In addition to his dissertations, Dr. Carballosa has authored numerous publications related to stem cell biology.
Director, Quality Systems
Oscar Robles has over thirty years of experience in pharmaceutical and medical device industries. His main areas of expertise are in Quality Systems, Quality Assurance, Manufacturing Systems Validation, Computerized Systems Validation, implementation of GxP Computerized Systems and ERP Systems such as TrackWise, Electronic Document Management, JDEwards, SAP, and Oracle. Prior to joining OrganaBio, Oscar was a member of the Quality Management team at Apotex – Aveva Drug Delivery Systems for ten years. Oscar has earned a Master’s in Business Administration from Nova Southeastern University and a Bachelor of Science in Electrical Engineering from Florida International University.
